Alaska Statutes Title 8. Business and Professions § 08.64.367. Use of amygdalin (laetrile); investigational drugs, biological products, or devices

(1) has a terminal illness;

(2) is ineligible or unable to participate in a current clinical trial for the investigational drug, biological product, or device;

(3) has considered, after consultation with the physician, all other treatment options currently approved by the United States Food and Drug Administration; and

(4) has given informed consent in writing for the use of the investigational drug, biological product, or device.

(1) “investigational drug, biological product, or device” means a drug, biological product, or device that has successfully completed Phase 1 studies of clinical trials for investigation and remains in ongoing clinical trials under Phase 2 or Phase 3 or is in the new drug application process following Phase 3 of clinical trials, but has not been approved for general use by the United States Food and Drug Administration;

(2) “terminal illness” means a disease that, without life-sustaining procedures, will result in death in the near future or a state of permanent unconsciousness from which recovery is unlikely.